CPR Invest - Silver Age - I EUR - Acc ISIN : LU1103787187
CPR Invest - Silver Age - I EUR - Acc
I(C) - LU1103787187
Asset class: Equities
YTD
As of 12/11/20269.78%
Risk IndicatorThe level of risk of the fund mainly reflects the risk of the market in which the fund is invested and, as the case may be, the leveraging strategy or inverse performance of the index. The capital initially invested does not benefit from any guarantee. The current level of risk does not indicate the future level of risk and may change over time. The lowest risk level is not equal to a risk-free investment.
1234567
Lower Risk
Higher Risk
The risk indicator assumes you keep the product according to the holding period.
NAV
As of 13/11/2026€205,600.00
SFDR ClassificationSustainable Finance Disclosure Regulation
Art. 8
Fund AUM
As of 13/11/2026€120.29M
The fund's investment objective is to outperform the European equity markets over the long-term (minimum five years) by capitalising on the growth of European stocks related to the ageing of the population.
NAVs
NAV from 17/11/2016 to 13/11/2026
Select period
Performance
Change in NAV in base 100
FundCPR Invest - Silver Age - I EUR - Acc (88.23% over the period)
Select period
Change in NAV in base 100Rolling performancesYear-on-year return (365 days)Annual returnsRisk indicatorsPerformances Scenarios
FundCPR Invest - Silver Age - I EUR - Acc (88.23% over the period)
Select period
Portfolio Analysis
Management commentary
Effective date: 31/10/2026Market Update
European markets rose by +1.9% in October, with the STOXX 600 at 646.75 points, bringing its YTD performance to 9.2%. The start of the month remained mainly driven by macroeconomic factors, including tensions in bond markets, geopolitical uncertainties, and oil price fluctuations. The start of the Q3 earnings season gradually shifted the market’s focus back to microeconomics (Q3 STOXX 600 EPS growth expected at +22% yoy, according to Bloomberg forecasts). This support allowed European equities to advance, but was not enough to dispel sovereign concerns, particularly pronounced in France. Political, social, and budgetary uncertainties pushed the 10-year OAT up to 5.15%, its highest level since 2002, and the OAT-Bund spread to 175 bps on October 22, the highest since 2011. The French yield even briefly exceeded that of the US Treasury, before returning to 4.94% (+11.5 bps for the month) after Moody’s maintained its Aa3 rating on the 23rd and Fitch its A+ rating on October 30 (although the outlook was downgraded). Oil also ended the month sharply higher, with Brent at $117.64 (+13.6%) and WTI at $104.12 (+15.2%), despite the gradual recovery of flows through Hormuz. The increase in attacks on ships and Saudi infrastructure, as well as the risk of new US-Israeli strikes against Iran after the midterm elections, have significantly increased the geopolitical risk premium.
On the macroeconomic front, October confirmed the resilience of global activity despite persistent inflationary pressures, placing central banks in an increasingly delicate balancing act. In the eurozone, GDP grew by +0.4% q/q in Q3, versus +0.2% expected, while the flash PMI fell to 51.9 in October, after 53.1 in September, but remained in expansion territory at the start of Q4. This resilience, however, masks divergent trajectories: Germany saw its inflation slow to +2.8% year-on-year in October, versus +3.0% expected and +3.3% in September, and recorded growth of +0.2% q/q, slightly above expectations, while France contracted by -0.1% q/q in Q3 and saw its national inflation accelerate to +3.4% year-on-year. In this context, the ECB kept its deposit rate at 2.50%, with the energy shock simultaneously increasing risks to both prices and growth, without yet significantly spreading to wages and core inflation. In the UK, activity also accelerated, with a composite PMI at 53.1, but inflation rose to +3.5%, reinforcing the prospect of a BoE rate hike in November. The US remains significantly more dynamic, with annualized growth of +3.4% in Q3, versus +2.2% in Q2, a composite PMI at 57.6, and jobless claims still low at 194k. Inflationary pressures remain persistent: headline PCE accelerated to +3.6% year-on-year in September, and core PCE to +3.1%, despite a slowdown in Q3 to +2.1% and +2.5% annualized, respectively. The Fed thus kept its rates at 3.75%-4.00%, but maintained a hawkish tone, leaving the door open for another hike.
At the sector level, healthcare (+14.1%) led by a wide margin, driven by UCB (+37.2%) and Financière de Tubize (+32.5%), which holds 36.3% of the laboratory. Boosted by Bimzelx in the US and Cimzia, UCB raised its 2026 targets for the second time, now expecting revenue growth of around 20% and adjusted EBITDA growth of +40% to +45% at constant exchange rates. Food and tobacco (+13.1%) benefited from solid earnings releases, with Imperial Brands (+20.2%) confirming its annual targets and announcing a new £1.5bn share buyback program, and Heineken (+16.1%), whose volumes rose by +4.8% in Q3 and net revenues by +4.6%, driven by double-digit growth in premium brands. Finally, energy (+8.7%) benefited from the nearly +13.6% rise in Brent, amid ongoing disruptions to Middle Eastern flows and escalating risks around Iran.
Conversely, banks (-10.6%) lagged behind, penalized by rising sovereign yields and widening spreads, which depreciated their bond portfolios and weighed particularly on Banco Santander (-17.9%), while NatWest (-15.8%) suffered from a flat net interest margin expected in 2027, against further growth anticipated by the market, as well as a 22% increase in provisions in Q3. Commodities (-8.5%) fell due to the drop in iron ore prices, amid fragile Chinese demand, but also company-specific factors, with lower gold and silver production at Fresnillo (-18.1%) and higher aluminum production costs at Norsk Hydro (-20.0%), while Rio Tinto (-14.2%) suffered from weak prices despite solid volumes.
Among stocks, Genmab (+67.0%) posted the best performance in the STOXX 600 after two major clinical successes: petosemtamab combined with pembrolizumab reduced the risk of death by 50% compared to pembrolizumab alone in head and neck cancer, and Rina-S reduced the risk of death by 57% in ovarian cancer. Wolters Kluwer (+28.5%) benefited from the launch of its first tax AI agents, capable of automatically preparing returns, realizing the monetization of AI in its professional software, as well as its share buyback program. Finally, EssilorLuxottica (+26.6%) benefited from a stronger-than-expected underlying Q3, with revenue of €7.49bn, up +7.2% at constant exchange rates, about 100 bps above consensus. The release was notably driven by the strength of legacy activities, with +10.6% growth in Direct-to-Consumer.
Portfolio Movements and Performance Analysis
Over the period from September 30 to October 30, 2026, the MSCI Europe rose by 2.15%. European equities evolved in an environment marked by rising energy prices linked to Middle East tensions, with Brent exceeding $110 per barrel, and high sovereign yields. French budget risk also weighed on domestic assets, while the OAT-Bund spread reached 170 bps. At the same time, stocks linked to artificial intelligence and semiconductors underwent unwinding, amid questions about monetization and investment financing. At the end of the period, the Fed and ECB maintained their rates, while eurozone GDP grew by 0.4% in the third quarter.
CPR Silver Age outperformed the MSCI Europe by +211 bps, with a gross performance of +4.26% versus +2.15% for the benchmark. Allocation contributed +266 bps, while selection weighed in at –51 bps. The absence of investment outside the investment universe contributed +129 bps. The main positive contributions came from the absence of investment in semiconductors – unwinding of the AI trade – ASML (+69 bps) and in banking, stressed by rate hikes and slowdown risks, HSBC (+37 bps) and Banco Santander (+28 bps).
Within the investment universe:
Pharmaceuticals were the top contributor, at +220 bps, including +191 bps from allocation and +30 bps from selection. Roche (+49 bps) rose by 19.3% amid quarterly revenue growth of 7% at constant exchange rates and confirmation of annual targets. Genmab (+44 bps) gained 67.0% after the publication of very positively received phase III results for Rina-S.
Healthcare Equipment added +23 bps, with +45 bps from allocation and –21 bps from selection. Air Liquide (+10 bps) rose by 5.9% after 3.0% organic quarterly growth and the announcement of a €1bn share buyback. Demant and EssilorLuxottica each contributed +6 bps; Demant gained 17.9% amid Oticon Zeal market share gains, while EssilorLuxottica rose by 26.6% after quarterly sales exceeded expectations.
Conversely, Robotics weighed in at –132 bps, including –115 bps from allocation and –18 bps from selection. Schneider Electric (–79 bps) fell by 18.7% in a context marked by the acquisition of PTC and its financing through a €6bn capital increase. ABB (–23 bps) declined by 8.1% despite solid orders, as the market reacted negatively to weaker growth in other activities.
Finally, Asset Managers weighed in at –64 bps, with +10 bps from allocation and –74 bps from selection. ING (–41 bps) fell by 10.3% after net profit came in 6% below consensus, despite a solid capital ratio.
Portfolio Movements
At the end of the period, we made adjustments by reducing our positions in private banks (Mediolanum, Banca Generali) and retirement insurers (ASR, ING) as well as in the best-performing pharmaceutical laboratories (Genmab, ArgenX, Sandoz, Galderma) to reposition ourselves in the robotics sector, which had fallen sharply (Schneider, ABB).
Risk Profile
The fund’s beta rose to 0.99, while tracking error decreased slightly to 5.22%. The breakdown of TE changed slightly compared to the previous month. The share of selection risk decreased to 30% of total active risk. Sector risk increased further, to 58%. The remainder, about 12%, is attributable to other components, notably currency risk (2%) and style risk (7%).
Thematic Outlook
In November, market direction should notably depend on the outcome of the US midterm elections on November 3, oil price trends, and monetary policy expectations. Historically, US markets have often risen after midterm elections, but this scenario remains conditional on energy price stabilization. A further escalation in the Middle East and a Brent price sustainably above $120 would, on the contrary, pose a risk to all equity markets. The Fed and ECB kept their rates unchanged in October, but markets still anticipate a hike in December in the face of persistent inflation.
In this context, the Silver Age strategy could continue to benefit from its exposure to defensive sectors and healthcare if investors remain focused on balance sheet quality, earnings visibility, and cash generation. Pharmaceuticals also have their own catalysts, linked to earnings releases and clinical advances, even if October’s strong contribution cannot be extrapolated. Conversely, an easing of yields and oil, accompanied by a return of risk appetite after the US elections, could favor a rebound in industrials, electrification, and robotics. Such a move could reduce the relative cost observed in October for this theme, provided that concerns about AI investment financing subside. The asset manager segment would remain more directly exposed to market trends, inflows, and financial conditions.
The relative profile of CPR Silver Age in November will therefore depend on the balance between, on the one hand, the continuation of the defensive rotation favoring healthcare and, on the other, a possible return to cyclical and technology sectors. Finally, the positive contribution from stocks absent from the universe cannot be considered sustainable: it could shrink or even reverse in the event of a rebound in banks, energy, or large European technology stocks. Diversification between healthcare, aging-related consumption, financial services, and automation will thus remain key to the strategy’s relative performance.
European markets rose by +1.9% in October, with the STOXX 600 at 646.75 points, bringing its YTD performance to 9.2%. The start of the month remained mainly driven by macroeconomic factors, including tensions in bond markets, geopolitical uncertainties, and oil price fluctuations. The start of the Q3 earnings season gradually shifted the market’s focus back to microeconomics (Q3 STOXX 600 EPS growth expected at +22% yoy, according to Bloomberg forecasts). This support allowed European equities to advance, but was not enough to dispel sovereign concerns, particularly pronounced in France. Political, social, and budgetary uncertainties pushed the 10-year OAT up to 5.15%, its highest level since 2002, and the OAT-Bund spread to 175 bps on October 22, the highest since 2011. The French yield even briefly exceeded that of the US Treasury, before returning to 4.94% (+11.5 bps for the month) after Moody’s maintained its Aa3 rating on the 23rd and Fitch its A+ rating on October 30 (although the outlook was downgraded). Oil also ended the month sharply higher, with Brent at $117.64 (+13.6%) and WTI at $104.12 (+15.2%), despite the gradual recovery of flows through Hormuz. The increase in attacks on ships and Saudi infrastructure, as well as the risk of new US-Israeli strikes against Iran after the midterm elections, have significantly increased the geopolitical risk premium.
On the macroeconomic front, October confirmed the resilience of global activity despite persistent inflationary pressures, placing central banks in an increasingly delicate balancing act. In the eurozone, GDP grew by +0.4% q/q in Q3, versus +0.2% expected, while the flash PMI fell to 51.9 in October, after 53.1 in September, but remained in expansion territory at the start of Q4. This resilience, however, masks divergent trajectories: Germany saw its inflation slow to +2.8% year-on-year in October, versus +3.0% expected and +3.3% in September, and recorded growth of +0.2% q/q, slightly above expectations, while France contracted by -0.1% q/q in Q3 and saw its national inflation accelerate to +3.4% year-on-year. In this context, the ECB kept its deposit rate at 2.50%, with the energy shock simultaneously increasing risks to both prices and growth, without yet significantly spreading to wages and core inflation. In the UK, activity also accelerated, with a composite PMI at 53.1, but inflation rose to +3.5%, reinforcing the prospect of a BoE rate hike in November. The US remains significantly more dynamic, with annualized growth of +3.4% in Q3, versus +2.2% in Q2, a composite PMI at 57.6, and jobless claims still low at 194k. Inflationary pressures remain persistent: headline PCE accelerated to +3.6% year-on-year in September, and core PCE to +3.1%, despite a slowdown in Q3 to +2.1% and +2.5% annualized, respectively. The Fed thus kept its rates at 3.75%-4.00%, but maintained a hawkish tone, leaving the door open for another hike.
At the sector level, healthcare (+14.1%) led by a wide margin, driven by UCB (+37.2%) and Financière de Tubize (+32.5%), which holds 36.3% of the laboratory. Boosted by Bimzelx in the US and Cimzia, UCB raised its 2026 targets for the second time, now expecting revenue growth of around 20% and adjusted EBITDA growth of +40% to +45% at constant exchange rates. Food and tobacco (+13.1%) benefited from solid earnings releases, with Imperial Brands (+20.2%) confirming its annual targets and announcing a new £1.5bn share buyback program, and Heineken (+16.1%), whose volumes rose by +4.8% in Q3 and net revenues by +4.6%, driven by double-digit growth in premium brands. Finally, energy (+8.7%) benefited from the nearly +13.6% rise in Brent, amid ongoing disruptions to Middle Eastern flows and escalating risks around Iran.
Conversely, banks (-10.6%) lagged behind, penalized by rising sovereign yields and widening spreads, which depreciated their bond portfolios and weighed particularly on Banco Santander (-17.9%), while NatWest (-15.8%) suffered from a flat net interest margin expected in 2027, against further growth anticipated by the market, as well as a 22% increase in provisions in Q3. Commodities (-8.5%) fell due to the drop in iron ore prices, amid fragile Chinese demand, but also company-specific factors, with lower gold and silver production at Fresnillo (-18.1%) and higher aluminum production costs at Norsk Hydro (-20.0%), while Rio Tinto (-14.2%) suffered from weak prices despite solid volumes.
Among stocks, Genmab (+67.0%) posted the best performance in the STOXX 600 after two major clinical successes: petosemtamab combined with pembrolizumab reduced the risk of death by 50% compared to pembrolizumab alone in head and neck cancer, and Rina-S reduced the risk of death by 57% in ovarian cancer. Wolters Kluwer (+28.5%) benefited from the launch of its first tax AI agents, capable of automatically preparing returns, realizing the monetization of AI in its professional software, as well as its share buyback program. Finally, EssilorLuxottica (+26.6%) benefited from a stronger-than-expected underlying Q3, with revenue of €7.49bn, up +7.2% at constant exchange rates, about 100 bps above consensus. The release was notably driven by the strength of legacy activities, with +10.6% growth in Direct-to-Consumer.
Portfolio Movements and Performance Analysis
Over the period from September 30 to October 30, 2026, the MSCI Europe rose by 2.15%. European equities evolved in an environment marked by rising energy prices linked to Middle East tensions, with Brent exceeding $110 per barrel, and high sovereign yields. French budget risk also weighed on domestic assets, while the OAT-Bund spread reached 170 bps. At the same time, stocks linked to artificial intelligence and semiconductors underwent unwinding, amid questions about monetization and investment financing. At the end of the period, the Fed and ECB maintained their rates, while eurozone GDP grew by 0.4% in the third quarter.
CPR Silver Age outperformed the MSCI Europe by +211 bps, with a gross performance of +4.26% versus +2.15% for the benchmark. Allocation contributed +266 bps, while selection weighed in at –51 bps. The absence of investment outside the investment universe contributed +129 bps. The main positive contributions came from the absence of investment in semiconductors – unwinding of the AI trade – ASML (+69 bps) and in banking, stressed by rate hikes and slowdown risks, HSBC (+37 bps) and Banco Santander (+28 bps).
Within the investment universe:
Pharmaceuticals were the top contributor, at +220 bps, including +191 bps from allocation and +30 bps from selection. Roche (+49 bps) rose by 19.3% amid quarterly revenue growth of 7% at constant exchange rates and confirmation of annual targets. Genmab (+44 bps) gained 67.0% after the publication of very positively received phase III results for Rina-S.
Healthcare Equipment added +23 bps, with +45 bps from allocation and –21 bps from selection. Air Liquide (+10 bps) rose by 5.9% after 3.0% organic quarterly growth and the announcement of a €1bn share buyback. Demant and EssilorLuxottica each contributed +6 bps; Demant gained 17.9% amid Oticon Zeal market share gains, while EssilorLuxottica rose by 26.6% after quarterly sales exceeded expectations.
Conversely, Robotics weighed in at –132 bps, including –115 bps from allocation and –18 bps from selection. Schneider Electric (–79 bps) fell by 18.7% in a context marked by the acquisition of PTC and its financing through a €6bn capital increase. ABB (–23 bps) declined by 8.1% despite solid orders, as the market reacted negatively to weaker growth in other activities.
Finally, Asset Managers weighed in at –64 bps, with +10 bps from allocation and –74 bps from selection. ING (–41 bps) fell by 10.3% after net profit came in 6% below consensus, despite a solid capital ratio.
Portfolio Movements
At the end of the period, we made adjustments by reducing our positions in private banks (Mediolanum, Banca Generali) and retirement insurers (ASR, ING) as well as in the best-performing pharmaceutical laboratories (Genmab, ArgenX, Sandoz, Galderma) to reposition ourselves in the robotics sector, which had fallen sharply (Schneider, ABB).
Risk Profile
The fund’s beta rose to 0.99, while tracking error decreased slightly to 5.22%. The breakdown of TE changed slightly compared to the previous month. The share of selection risk decreased to 30% of total active risk. Sector risk increased further, to 58%. The remainder, about 12%, is attributable to other components, notably currency risk (2%) and style risk (7%).
Thematic Outlook
In November, market direction should notably depend on the outcome of the US midterm elections on November 3, oil price trends, and monetary policy expectations. Historically, US markets have often risen after midterm elections, but this scenario remains conditional on energy price stabilization. A further escalation in the Middle East and a Brent price sustainably above $120 would, on the contrary, pose a risk to all equity markets. The Fed and ECB kept their rates unchanged in October, but markets still anticipate a hike in December in the face of persistent inflation.
In this context, the Silver Age strategy could continue to benefit from its exposure to defensive sectors and healthcare if investors remain focused on balance sheet quality, earnings visibility, and cash generation. Pharmaceuticals also have their own catalysts, linked to earnings releases and clinical advances, even if October’s strong contribution cannot be extrapolated. Conversely, an easing of yields and oil, accompanied by a return of risk appetite after the US elections, could favor a rebound in industrials, electrification, and robotics. Such a move could reduce the relative cost observed in October for this theme, provided that concerns about AI investment financing subside. The asset manager segment would remain more directly exposed to market trends, inflows, and financial conditions.
The relative profile of CPR Silver Age in November will therefore depend on the balance between, on the one hand, the continuation of the defensive rotation favoring healthcare and, on the other, a possible return to cyclical and technology sectors. Finally, the positive contribution from stocks absent from the universe cannot be considered sustainable: it could shrink or even reverse in the event of a rebound in banks, energy, or large European technology stocks. Diversification between healthcare, aging-related consumption, financial services, and automation will thus remain key to the strategy’s relative performance.
Characteristics
General data
Inception date
29/08/2014First Nav Date
22/12/2009Currency
EURShow more
Valuation
DailyMinimum initial investment
100000 eurosMinimum additional investment
1 10/1000° share(s)/equityCosts Composition
| One-off costs upon entry or exit (Investment EUR 10,000) | If you exit after 1 year | ||
| Entry costs | This includes distribution costs of 5.00% of amount invested. This is the most you will be charged. The person selling you the product will inform you of the actual charge. | Up to €500.00 | |
| Exit costs | We do not charge an exit fee for this product, but the person selling you the product may do so. | €0.00 | |
| Ongoing costs taken each year (Investment EUR 10,000) | |||
| Management fees and other administrative or operating costs | 1.28% of the value of your investment per year. This percentage is based on actual costs over the last year. | €121.20 | |
| Transaction costs | We do not charge a transaction fee for this product | €0.00 | |
| Incidental costs taken under specific conditions (Investment EUR 10,000) | |||
| Performance fees | 15.00% annual outperformance of the reference asset 100% MSCI EUROPE NR Close + 1%. The calculation applies on each Net Asset Value calculation date in accordance with the terms described in the prospectus. Past underperformances over the last 5 years should be clawed back before any new accrual of performance fee.The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years. The performance fee is paid even if the performance of the share over the performance observation period is negative, while remaining higher than the performance of the Reference Asset. | €0.00 | |
Codification
ISIN code
LU1103787187Bloomberg code
CPRSAIC LXReuters code
LP68277369Investment Objective
The fund's investment objective is to outperform the European equity markets over the long-term (minimum five years) by capitalising on the growth of European stocks related to the ageing of the population.
Documents
| Language | Documents | Type | Closing Date |
|---|---|---|---|
SV | PDF | 01/09/2026 | |
EN | PDF | 31/07/2025 | |
PDF | 01/10/2026 | ||
PDF | 31/01/2026 | ||
SV | PDF | 31/10/2026 | |
EN | PDF | 26/10/2016 |
Sustainability-related disclosures
| Language | Documents | Type | Closing Date |
|---|---|---|---|
SV | PDF | 01/01/2025 | |
EN | PDF | 03/08/2026 |